Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource, 1 online resource.
Sprache
Englisch

Erschienen in
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial ; volume:29 ; number:8 ; day:24 ; month:7 ; year:2023 ; pages:2110-2120 ; date:8.2023
Nature medicine ; 29, Heft 8 (24.7.2023), 2110-2120, 8.2023

Urheber
Mosele, Fernanda
Deluche, Elise
Lusque, Amelie
Le Bescond, Loïc
Filleron, Thomas
Pradat, Yoann
Ducoulombier, Agnes
Pistilli, Barbara
Bachelot, Thomas
Viret, Frederic
Levy, Christelle
Signolle, Nicolas
Alfaro, Alexia
Tran, Diep T. N.
Garberis, Ingrid Judith
Talbot, Hugues
Christodoulidis, Stergios
Vakalopoulou, Maria
Droin, Nathalie
Stourm, Aurelie
Kobayashi, Maki
Kakegawa, Tomoya
Lacroix, Ludovic
Saulnier, Patrick
Job, Bastien
Deloger, Marc
Jimenez, Marta
Mahier, Celine
Baris, Vianney
Laplante, Pierre
Kannouche, Patricia
Marty, Virginie
Lacroix-Triki, Magali
Diéras, Veronique
André, Fabrice
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1038/s41591-023-02478-2
URN
urn:nbn:de:101:1-2023110310334569036538
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:50 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Mosele, Fernanda
  • Deluche, Elise
  • Lusque, Amelie
  • Le Bescond, Loïc
  • Filleron, Thomas
  • Pradat, Yoann
  • Ducoulombier, Agnes
  • Pistilli, Barbara
  • Bachelot, Thomas
  • Viret, Frederic
  • Levy, Christelle
  • Signolle, Nicolas
  • Alfaro, Alexia
  • Tran, Diep T. N.
  • Garberis, Ingrid Judith
  • Talbot, Hugues
  • Christodoulidis, Stergios
  • Vakalopoulou, Maria
  • Droin, Nathalie
  • Stourm, Aurelie
  • Kobayashi, Maki
  • Kakegawa, Tomoya
  • Lacroix, Ludovic
  • Saulnier, Patrick
  • Job, Bastien
  • Deloger, Marc
  • Jimenez, Marta
  • Mahier, Celine
  • Baris, Vianney
  • Laplante, Pierre
  • Kannouche, Patricia
  • Marty, Virginie
  • Lacroix-Triki, Magali
  • Diéras, Veronique
  • André, Fabrice
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

Verbundene Objekte